Saturday, June 7, 2014

Reata Enrolls First Patient In Promising, New Pulmonary Arterial Hypertension Trial

BioNews Texas - Irving-based Reata Pharmaceuticals, a privately held company aiming to translate the company’s groundbreaking research into new therapies, has enrolled the first patient in a Phase 2 dose-ranging study that will examine the safety, tolerability, and efficacy of bardoxolone methyl in patients with pulmonary arterial hypertension (PAH).

Read article | Learn more about other PH clinical trials

No comments: